



July 4, 2017

**BSE Limited**  
Floor 25, P. J. Towers  
Dalal Street, Fort  
**Mumbai - 400 001**

**National Stock Exchange of India Limited**  
Exchange Plaza  
Bandra Kurla Complex  
Bandra (E)  
**Mumbai - 400 051**

Dear Sirs,

**Sub.: Schedule of Investor Conference Call for Jubilant Life Sciences Limited - Unaudited Financial Results for the quarter ended June 30, 2017**

Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company is organising a Conference Call on July 18, 2017 after submission of the financial results for the quarter ended June 30, 2017 to the Stock Exchanges. The details of Conference Call are attached.

This is for information and record.

Thanking you,

Yours faithfully,  
For Jubilant Life Sciences Limited

  
Rajiv Shah  
↓ Company Secretary ✓

Encl.: as above

**A Jubilant Bhartia Company**

OUR VALUES



**Jubilant Life Sciences Limited**

1-A, Sector 16-A,  
Noida-201 301, UP, India  
Tel: +91 120 4361000  
Fax: +91 120 4234895-96  
www.jubl.com

Regd Office:  
Bhartiagram, Gajraula  
Distt. Amroha - 244 223,  
UP, India  
CIN : L24116UP1978PLC004624



**Jubilant Life Sciences Limited**

1A, Sector 16A, Noida 201301, India

Tel. : +91 120 4361000

www.jubl.com

**Noida, Tuesday July 04, 2017**

### **Conference call on Tuesday, July 18, 2017 at 05:00 pm IST**

The management team of Jubilant Life Sciences Limited (Jubilant) – an integrated global pharmaceutical and life sciences company will host a **conference call for analysts and investors on Tuesday, July 18, 2017 at 05:00 pm IST**. The call will commence with a brief management discussion on the financial performance for the quarter ended June 30<sup>th</sup>, 2017, followed by an interactive Question & Answer session.

Mr. Shyam S. Bhartia, Chairman, Mr. Hari S. Bhartia, Co-Chairman & Managing Director, Mr. R Sankaraiah, Executive Director – Finance, Mr. Ravi Agrawal, Head - Investor Relations and Mr. Anupam Jain, Manager – Investor Relations, Jubilant Life Sciences Limited, will represent the management team at the conference call.

#### **Conference Dial-In Numbers**

**Primary Number: +91 22 3938 1071**

*The number listed above is universally accessible from all networks and all countries.*

**Local Access Number: 3940 3977**  
*Available in - Ahmedabad, Bengaluru, Chandigarh, Chennai, Cochin, Gurgaon (NCR), Hyderabad, Kolkata, Pune, Lucknow. Accessible from all carriers.*

**Toll Free Number:**  
USA: **1 866 746 2133**  
UK: **0 808 101 1573**  
Singapore: **800 101 2045**  
Hong Kong: **800 964 448**

**Replay facility available from June 18 to 24, 2017**

**Dial in No.: +91 22 3065 2322**

**Playback ID: 90393#**

**-ENDS -**

## About Jubilant Life Sciences Limited

Jubilant Life Sciences Limited is an integrated global pharmaceutical and life sciences company engaged in Pharmaceuticals, Life Science Ingredients and Drug Discovery Solutions. The Pharmaceuticals segment, through its wholly owned subsidiary Jubilant Pharma Limited, is engaged in manufacture and supply of APIs, Solid Dosage Formulations, Radiopharmaceuticals, Allergy Therapy Products and Contract Manufacturing of Sterile and Non-sterile products through 6 USFDA approved manufacturing facilities in India, USA and Canada. The Life Science Ingredients segment, is engaged in Specialty Intermediates, Nutritional Products and Life Science Chemicals through 5 manufacturing facilities in India. The Drug Discovery Solutions segment, provides proprietary in-house innovation & collaborative research and partnership for out-licensing through 3 world class research centres in India and USA. Jubilant Life Sciences Limited has a team of around 6,700 multicultural people across the globe and is committed to deliver value to its customers across over 100 countries. The Company is well recognized as a 'Partner of Choice' by leading pharmaceuticals and life sciences companies globally. For more info: [www.jubl.com](http://www.jubl.com).

### For more information please contact:

Ravi Agrawal / Anupam Jain  
Jubilant Life Sciences Limited  
Ph: +91-120 4361002 / 21  
E-mail: [ravi\\_agrawal@jubl.com](mailto:ravi_agrawal@jubl.com)  
[anupam\\_jain@jubl.com](mailto:anupam_jain@jubl.com)

Siddharth Rangnekar / Karl Kolah  
CDR India  
Ph: +91-22 6645 1209 / 20  
E-mail: [siddharth@cdr-india.com](mailto:siddharth@cdr-india.com)  
[karl@cdr-india.com](mailto:karl@cdr-india.com)

**Disclaimer:** Statements made on the call relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward-looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Life Sciences may, from time to time, make additional written and oral forward looking statements, including statements contained in the company's filings with the regulatory bodies and its reports to shareholders. The company assumes no obligation to update forward-looking statements to reflect actual results, changed assumptions or other factors.